Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer

Aung, Phyu P.; Oue, Naohide; Mitani, Yoshitsugu; Nakayama, Hirofumi; Yoshida, Kazuhiro; Noguchi, Tsuyoshi; Bosserhoff, Anja‐Katrin; Yasui, Wataru

doi:10.1038/sj.onc.1209279

Cited by 155 publications

(146 citation statements)

References 46 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…Only matrix metalloproteinase 10 (MMP10), the iron-binding protein lactotransferrin (LTF), and the serine protease inhibitor serpin A3 (SERPINA3) showed increased expression in the aggressive phenotypes independent of site. Recent work has established the increased expression of MMP10 in oral tongue squamous cell cancer, non-small cell lung cancer (NSCLC), and gastric cancer [17][18][19]. In the case of gastric cancer, levels of MMP10 were correlated with poor prognosis in advanced gastric cancer [19].…”

Section: Discussionmentioning

confidence: 99%

“…Recent work has established the increased expression of MMP10 in oral tongue squamous cell cancer, non-small cell lung cancer (NSCLC), and gastric cancer [17][18][19]. In the case of gastric cancer, levels of MMP10 were correlated with poor prognosis in advanced gastric cancer [19]. From the downregulated genes, only a single gene (WIF-1) was seen as down-regulated in data from all three anatomic sites.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Site-Specific Molecular Signatures Predict Aggressive Disease in HNSCC

Belbin

Smith

Adrien

et al. 2008

Head and Neck Pathol

View full text Add to dashboard Cite

It is known that head and neck squamous cell carcinomas (HNSCC) originating from different anatomic locations can exhibit varying behavior that is not predictable by histopathology of the primary tumor. Using a microarray containing 27,323 cDNA clones, we generated sets of gene expression profiles for 36 HNSCC primary tumors (12 oral cavity, 12 oropharynx, and 12 larynx/ hypopharynx). From these datasets, we ranked genes according to their ability to differentiate between patients whose disease progressed within a 24 month period (aggressive phenotype) and those that did not (nonaggressive phenotype) based on levels of gene expression. A merging of datasets from the three sites revealed that only a fraction of identified genes were shared between any two sites. This contrasted greatly with the significant overlap (approximately 50%) in down-regulated genes identified in tumor/normal comparisons using cases both from oropharynx and larynx/hypopharynx. From these data, we conclude that HNSCC tumors originating from different anatomic sites share consistent changes in gene expression when comparing primary tumors to normal adjacent mucosa; these common changes most likely reflect alterations required for tumor development. In contrast, once a tumor has developed, tumor-host interactions at the different anatomic sites are likely responsible for the site-specific signatures associated with aggressive versus non-aggressive disease. Predictions of outcome based on gene expression profiling are therefore heavily influenced by the anatomic site of the primary tumor.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Site-Specific Molecular Signatures Predict Aggressive Disease in HNSCC

Belbin

Smith

Adrien

et al. 2008

Head and Neck Pathol

View full text Add to dashboard Cite

show abstract

“…We previously performed serial analysis of gene expression (SAGE) of four primary GCs and identified several GC-specific genes (Aung et al, 2006). Of these genes, Regenerating gene family (REG), member 4 (REG4, which encodes Reg IV) is a candidate gene for cancer-specific expression, at least in patients with GC.…”

Section: Introductionmentioning

confidence: 99%

Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy

et al. 2007

Self Cite

View full text Add to dashboard Cite

“…3 We previously performed Serial Analysis of Gene Expression (SAGE) on 4 primary GCs 4 and identified several GC-specific genes. 5 Of these genes, regenerating islet-derived family, member 4 (REG4, which encodes Reg IV) is a candidate gene for cancer-specific expression. Reg IV is expressed in 30% of GCs and is associated with both the intestinal mucin phenotype and neuroendocrine differentiation.…”

mentioning

confidence: 99%

“…In addition to Reg IV, olfactomedin 4 (OLFM4, also known as GW112 or hGC-1) is a candidate gene for cancer-specific expression, at least in patients with GC. 5 OLFM4 was originally cloned from human haematopoietic myeloid cells. 8 Although OLFM4 is predominantly expressed in bone marrow, small intestine, colon and prostate, 8 the levels of expression are much lower in normal tissues than in GC tissues.…”

mentioning

confidence: 99%

Serum olfactomedin 4 (GW112, hGC‐1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients

Oue

Sentani

Noguchi

et al. 2009

Intl Journal of Cancer

104

View full text Add to dashboard Cite

Gastric cancer (GC) is 1 of the most common human cancers. Early detection remains the most promising approach to improving long‐term survival of patients with GC. We previously performed Serial Analysis of Gene Expression (SAGE) on 4 primary GCs and identified several GC‐specific genes including Reg IV. Of these genes, olfactomedin 4 (OLFM4, also known as GW112 or hGC‐1) is a candidate gene for cancer‐specific expression. In this study, we examined the expression of olfactomedin 4 in human GC by immunohistochemistry. We also assessed serum olfactomedin 4 levels in GC patients by enzyme‐linked immunosorbent assay. 94 (56%) of 167 GC cases were positive for olfactomedin 4 by immunostaining. Olfactomedin 4 staining was observed more frequently in stage I/II cases than in stage III/IV cases. The serum olfactomedin 4 concentration in presurgical GC patients (n = 123, mean ± SE, 36.3 ± 3.5 ng/mL) was significantly higher than that in healthy individuals (n = 76, 16.6 ± 1.6 ng/mL). In patients with stage I GC, the sensitivity of serum olfactomedin 4 (25%) and Reg IV (35%) was superior to that of CA19‐9 (5%) or CEA (3%). Furthermore, in patients with stage I GC, the combination of olfactomedin 4 and Reg IV elevated the diagnostic sensitivity to 52%. These results suggest that serum olfactomedin 4 is a useful marker for GC and its measurement alone or in combination with Reg IV has utility in the early detection of GC. © 2009 UICC

show abstract

Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer

Cited by 155 publications

References 46 publications

Site-Specific Molecular Signatures Predict Aggressive Disease in HNSCC

Site-Specific Molecular Signatures Predict Aggressive Disease in HNSCC

Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy

Serum olfactomedin 4 (GW112, hGC‐1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients

Contact Info

Product

Resources

About